OriGene Technologies, Inc.
9620 Medical Center Drive, Ste 200
Rockville, MD 20850, US
Phone: +1-888-267-4436
https://www.origene.com
techsupport@origene.com
EU: info-de@origene.com
CN: techsupport@origene.cn

Product datasheet for AM32094PU-N

Tenascin C (TNC) Mouse Monoclonal Antibody [Clone ID: DB7]

Product data:

Product Type:	Primary Antibodies
Clone Name:	DB7
Applications:	IF, IHC, IP, WB
Recommended Dilution:	**Western blotting.** **Immunofluorescence.** **immunoprecipitation.** **Immunohistochemistry on Formalin-Fixed, Paraffin-Embedded Sections.** **Quantitation of Tn-C in body fluids** together with clone EB2 Cat.-No AM32095PU-N (ref. 9).
Reactivity:	Human
Host:	Mouse
Isotype:	IgG2a
Clonality:	Monoclonal
Immunogen:	Tenascin polypeptides isolated from spent culture supernatant of human fibroblasts isolated by affinity chromatography. Hybridoma produced by fusion between myeloma cells and Balb/c spleen cells.
Specificity:	The antibody recognizes the Mr 250000 and 180000 Human Tenascin polypeptides in Immunoprecipitation and in Immunoblots the Mr 250000 polypeptide. The antibody reacts with the fibrinogen-like knob-domain of Tenascin protein.
Formulation:	PBS State: Ig Fraction State: Liquid Ig fraction Stabilizer: 1.0% BSA Preservative: 0.09% Sodium Azide
Concentration:	lot specific
Conjugation:	Unconjugated
Storage:	Store the antibody undiluted at 2-8°C.
Stability:	Shelf life: one year from despatch.
Gene Name:	tenascin C

View online »

Database Link: Entrez Gene 3371 Human
P24821

Background: Tenascins were first characterized in the early 1980's. Since then hundreds of publications on tenascin in normal tissues, pathologically reactive tissues and carcinomas have been published. However, only recently more elective studies have been done. In these studies retrospective material from pathology files has been studied as well as larger fresh material collected during several years from patients. These studies have now attempted to reveal more specific points in carcinogenesis and pathological tissue reactions.
It has been demonstrated that tenascin immunoreactivity in breast carcinoma cells could be indicative of metastasis and survival. Recent studies using retrospective material showed that the expression of tenascin in invasion border of early breast cancer significantly correlates with higher risk of distant metastasis. These studies have been continued now and the preliminary results clearly suggest that expression of tenascin in invasion border of early breast cancer is significantly associated with proliferative activity and higher risk of local recurrence. This result implicates a wide application for tenascin antibodies in the breast pathology.
The point is that tenascin expression may suggest situations in which even small breast carcinomas may need more intensive complementary therapy (chemotherapy etc.). Recent studies have also shown that tenascin is significantly increased in airway basement membrane of asthmatics and rapidly decreases by inhaled steroid. This result suggests that tenascin expression may be used to monitor the disease status and outcome of treatment in different types of asthma.

Synonyms: Tenascin-C, TN-C, Hexabrachion, Cytotactin, Neuronectin, GMEM